|Bid||0.8400 x 0|
|Ask||0.8800 x 0|
|Day's Range||0.8400 - 0.8800|
|52 Week Range||0.4300 - 1.2000|
|Beta (5Y Monthly)||1.67|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 16, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MUNICH, Nov. 23, 2020 /CNW/ -- MYT Netherlands Parent B.
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI) (OTCQX: NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three and nine months ended September 30, 2020. For further details on the results, please refer to Nuvo's Management, Discussion and Analysis (MD&A;) and Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2020 which are available on the Company's website (www.nuvopharmaceuticals.com). All figures are in Canadian dollars, unless otherwise noted.
Jesse Ledger became the CEO of Nuvo Pharmaceuticals Inc. (TSE:NRI) in 2017, and we think it's a good time to look at...